Blunting macrophage accumulation, through osteopontin or monocyte chemoattractant protein-1/chemokine (C-C motif) ligand 2 (MCP-1/CCL2) inhibition, or ablation of specific subsets of macrophages induces an improvement of different aspects of NASH and metabolic syndrome, namely inflammatory activity, insulin resistance and hepatic fibrosis [30]. The gene discussed is CCL2; the disease is metabolic syndrome.